Association of the rs1611115 polymorphism in DBH gene with Parkinson's disease: a meta-analysis.
A meta-analysis was performed to assess the association between the dopamine beta-hydroxylase (DBH) rs1611115 genetic polymorphism and Parkinson's disease (PD). A comprehensive search was conducted to identify all case-control or cohort studies. The fixed or random effect-pooled measure was selected on the basis of a homogeneity test among studies. Heterogeneity among studies was evaluated using the I2. We performed sensitivity analyses to evaluate the robustness of the results. Publication bias was estimated using Egger's linear regression test. Five case-control studies corresponded to the inclusion criteria comprising 3926 patients and 3542 controls which were included in the present meta-analysis. Our meta-analysis showed no significant association between DBH rs1611115 genetic polymorphism and risk of PD in the codominant (REM, OR = 1.017, 95%CI = 0.854-1.210), dominant (REM, OR = 0.989, 95%CI = 0.826-1.185), and recessive (REM, OR = 1.007, 95%CI = 0.657-1.542) models. Moreover, in the subgroup analysis based on region (Asia and Europe), no significant associations were observed in Asia or Europe. This meta-analysis suggests that the DBH rs1611115 genetic polymorphism might not be associated with PD.